Returning corporate investors Takeda Ventures and MRL Ventures Fund helped the cancer immunotherapy developer take its total funding to over $225m.
US-based immuno-oncology drug developer Xilio Therapeutics has completed a $95m series C round featuring Takeda Ventures and MRL Ventures Fund, which invested on behalf of pharmaceutical firms Takeda and Merck & Co.
Hedge fund manager Rock Springs Capital led the round, which included Bain Capital Life Sciences, a vehicle for private equity firm Bain Capital, in addition to Deerfield Management, RA Capital Management, Atlas Venture, SV Health Investors and RiverVest Venture Partners.
Formerly known as Akrevia Therapeutics, Xilio is developing…
